Related by context. All words. (Click for frequent words.) 83 Reduces Risk 82 Improves Survival 81 Significantly Improves 81 Demonstrates Significant 81 Significantly Reduced 79 Study Demonstrates 79 Improves Outcomes 78 Helps Reduce 78 Prolongs Survival 78 Announces FDA Clearance 78 Significantly Improved 78 FDA Clears 78 FDA Okays 77 Shows Promise 77 Significantly Increases 77 Elderly Patients 77 Completes Enrollment 77 Demonstrates Positive 77 Lowers Risk 77 Meets Primary Endpoint 77 Dramatically Increases 77 Improves Quality 76 Patients Treated With 76 Study Proves 76 Single Dose 76 Receives Orphan Drug Designation 76 Proven Effective 76 Patients Treated 76 FDA Approvals 76 Increases Risk 76 Submits NDA 76 Files IND 76 Completes Patient Enrollment 76 Pediatric Patients 76 Patients Undergoing 76 Appears Safe 76 Awarded Patent 76 Clinical Trial Results 76 Significantly Reduce 76 Initiates Clinical Trial 75 Effective Than 75 Hypertensive Patients 75 Patients Receiving 75 Receives Patent 75 Randomized Trials 75 Shows Promising 75 Drug Candidate 75 Study Indicates 75 Shows Efficacy 75 Introduces Next Generation 75 Present Preclinical Data 75 Dramatically Reduces 75 Receives FDA Clearance 75 Previously Treated 75 Showed Significant 75 Reduce Risk 75 Effectively Treats 75 Is Well Tolerated 75 Files Patent Application 75 Clinical Trial Evaluating 75 Dramatically Improves 75 Osteoporosis Drug 75 Helps Prevent 75 Significant Improvement 75 Gets FDA Clearance 75 Provide Comprehensive 74 Phase IIb Trial 74 Adjuvant Treatment 74 Demonstrates Statistically Significant 74 Presents Positive 74 Presents Preclinical Data 74 Improves Efficiency 74 Reduced Risk 74 Demonstrates Superior 74 Treated Patients 74 Knee Osteoarthritis 74 Data Suggest 74 Improve Survival 74 Improved Survival 74 Combination Treatment 74 Proves Effective 74 Bone Metastases 74 Receives Approvable Letter 74 Survival Benefit 74 Slow Progression 74 Demonstrated Significant 74 Postmenopausal Women 74 Advanced Melanoma 74 Adjunctive Therapy 74 Study Confirms 74 Demonstrates Potential 74 Significant Increase 74 Phase III Trial 74 Novel Oral 74 Achieves Milestone 74 Shows Promise Against 74 Announces Immediate Availability 74 Induces 74 Inhibits 73 Mitigates 73 Orally Active 73 Initiates Clinical Trials 73 Strengthens Position 73 Cholesterol Lowering Drug 73 Increased Risk 73 Rheumatoid Arthritis Patients 73 Drug Fails 73 Amplifies 73 Lupus Drug 73 Announces Publication 73 Boosts Productivity 73 Protects Against 73 Phase 2b Clinical Trial 73 Releases Next Generation 73 Submits Application 73 Chronic Hepatitis C 73 Obese Patients 73 Study Evaluating 73 Reduces Pain 73 Receives SFDA Approval 73 Successfully Completed 73 Generic Versions 73 Phase 2b Trial 73 Meta Analysis 73 Study Shows Benefits 73 Breast Cancer Recurrence 73 FDA Approves 73 Kidney Function 73 Fracture Risk 73 Phase IIb Clinical Trial 73 Secondary Hyperparathyroidism 73 Prophylactic Treatment 73 Low Dose 73 Statistically Significant 73 Being Studied 73 Investigational Compound 73 Protease Inhibitor 73 Drug Shows Promise 73 Study Compares 73 Gout Drug 72 Initiate Clinical Trial 72 Treatment Reduces 72 Initiates Enrollment 72 Platform Enables 72 Antitumor Activity 72 Arthritis Drug 72 Announce Availability 72 Therapy Reduces 72 Receives Positive 72 Launches Next Generation 72 Reveals Positive 72 Guidelines Issued 72 Mylan Receives Approval 72 Reports Positive 72 Introduces Revolutionary 72 Heart Failure Patients 72 Announces Initiation 72 Phase IIa Clinical Trial 72 Plaque Psoriasis 72 Unfractionated Heparin 72 Levels Linked 72 Study Shows Significant 72 Unveils Next Generation 72 Phase 2a Trial 72 Prostate Cancer Patients 72 Long Term Efficacy 72 Announce License Agreement 72 Helps Predict 72 Demonstrates Efficacy 72 Increases Productivity 72 Transdermal Patch 72 FDA Warns 72 Achieves Highest 72 Combo Therapy 72 Introduces Breakthrough 72 Anti Inflammatory 72 Inhaled Corticosteroids 72 Osteoporosis Drugs 72 Clinical Outcome 72 Reduces Cost 72 Sign License Agreement 72 Trial Evaluating 72 Significant Reduction 72 Commercializes 72 Study Identifies 72 Expanded Indication 72 Anti Tumor Activity 72 Proves Successful 72 Cardiovascular Events 72 Patient Enrollment 72 Receives Favorable 72 Combination Therapy 72 Report Indicates 72 Sign Licensing Agreement 72 Achieves Positive 72 IND Application 72 Prove Effective 72 Helps Relieve 72 Provides Guidance 72 Lowers Blood Pressure 72 Delivers Unprecedented 72 Well Tolerated 72 Rheumatoid Arthritis Drug 72 Jointly Announce 72 Demonstrates Sustained 72 Delivers Next Generation 72 Begins Shipment 72 Cuts Costs 72 Potentially Fatal 72 Severe Sepsis 72 Hormone Receptor Positive 72 Tumor Growth 72 Significant Improvements 72 Releases Latest 72 Widely Used 72 Patients Suffering 72 Introduces Enhanced 72 Announces License Agreement 71 Left Ventricular Hypertrophy 71 Initiates Phase III 71 Treating Chronic 71 Relapsing Multiple Sclerosis 71 Anticancer Activity 71 Premenopausal Women 71 Teva Provides Update 71 Fungal Infections 71 Carotid Stenting 71 Epilepsy Drug 71 Unveils Latest 71 Venous Thromboembolism 71 Orthostatic Hypotension 71 Versus Placebo 71 Helps Ensure 71 Pooled Analysis 71 Advanced Prostate Cancer 71 Provides Unprecedented 71 Phase III Clinical Trial 71 Announces Enhancements 71 Gene Variant 71 Prolongs 71 Can Predict 71 Announce Collaboration Agreement 71 Study Examines 71 Osteoarthritis Pain 71 Delivers Breakthrough 71 Clinical Evaluation 71 Solution Delivers 71 NDA Submission 71 Study Showed 71 Study Validates 71 Expand Collaboration 71 Osteoporosis Treatment 71 Phospholipase A2 71 Oral Fingolimod 71 Jumps Higher 71 Correlation Between 71 Provides Comprehensive 71 Controlled Study 71 Discontinues 71 Receives Positive Opinion 71 Fewer Side Effects 71 Predict Response 71 Receives Clearance 71 HER2 Positive 71 Helps Ease 71 Critically Ill Patients 71 Shown Effective 71 Clinical Efficacy 71 Expands Capabilities 71 Anti Tumor 71 Settle Patent Litigation 71 Eases Pain 71 Preclinical Data 71 Newly Diagnosed Multiple Myeloma 71 Investigational Drug 71 Advanced Colorectal Cancer 71 Renal Cell Carcinoma 71 Launches Enhanced 71 Test Detects 71 ORLive Presents 71 Previously Untreated 71 Helps Identify 71 Statin Therapy 71 Patent Issued 71 Achieves Record Sales 71 Controlled Trial 71 Regains Compliance 71 Expands Scope 71 Slows Progression 71 Improves Productivity 71 Continues Momentum 71 Announces Tentative Approval 71 Delivers Enhanced 71 Novel Compound 71 Initiate Phase III 71 Announce Merger Agreement 71 Generic Version 71 Introduces Innovative 71 Dramatically Reduce 71 Significantly Improve 71 Attenuates 71 Completes Transition 71 Develop Novel 70 Multiplies 70 Monotherapy 70 Files Patent 70 FDA Panel Recommends 70 Better Manage 70 Releases Enhanced 70 Blood Pressure Drug 70 Enrolls First 70 Confirms Efficacy 70 Differentiates 70 Immunomedics Announces 70 Introduces Powerful 70 Help Reduce 70 Greatly Reduces 70 Obesity Linked 70 Enlarged Prostate 70 Announces Licensing Agreement 70 Non Responders 70 Accelerate Adoption 70 Migraine Drug 70 PPD Declares 70 Quadruples 70 Abdominal Pain 70 Adjuvant Therapy 70 Identifies Potential 70 Reduces Mortality 70 Beneficial Effects 70 Hepatitis C Genotype 70 Announces Positive 70 Helps Manage 70 Completes Integration 70 Chronic Hepatitis B 70 Report Analyzes 70 Hemodialysis Patients 70 Granted Orphan Drug 70 Study Evaluates 70 Completes Tender Offer 70 Node Positive 70 PRN FDA Approves 70 Alleviates 70 Successfully Completes Phase 70 Psoriasis Drug 70 Non Invasive Treatment 70 Shingles Vaccine 70 Patent Covering 70 Help Detect 70 Therapy Improves 70 Expands Portfolio 70 Lower Than Expected 70 Viral Load 70 Introduces Unique 70 Reconfirms 70 Attains 70 Diabetic Patients 70 BioSante Pharmaceuticals Announces 70 Announce Settlement 70 Deliver Powerful 70 Combination REOLYSIN R 70 Recommends Approval 70 Launches Generic Version 70 Receives Certification 70 FDA Approves Drug 70 Cholesterol Lowering 70 Tyrosine Kinase Inhibitor 70 Initiates Phase II 70 Begins Dosing 70 AnaSpec Introduces 70 Genes Linked 70 Q4 Loss Narrows 70 Receives Milestone Payment 70 Overactive Bladder 70 Outperforms 70 Resistant Hypertension 70 Pivotal Study 70 FDA Accepts 70 Bare Metal Stents 70 Lowers Costs 70 Study Reinforces 70 Menopausal Symptoms 70 Unveils Revolutionary 70 Contrast Agents 70 Holds Promise 70 Cholesterol Levels 70 Could Prevent 70 Mouse Model 70 Study Suggests 70 Strengthens Balance Sheet 70 Phase 2b Study 70 Study Analyzes 70 Offers Unprecedented 70 Sirolimus Eluting Stent 70 Extends Leadership 70 Announce Collaboration 70 Desvenlafaxine Succinate 70 Achieves Record 70 Announce Licensing Agreement 70 FDA Warns Against 70 Adverse Effects 70 Empowers Consumers 70 Improve Patient 70 Relapsed Refractory 70 Receives Tentative Approval 70 Sees Continued Growth 69 Spinal Fusion 69 Impairs 69 Univest Corporation Declares 69 Announces Issuance 69 Eliminates Need 69 Poorly Controlled 69 Symptom Relief 69 Drug Prevents 69 Relieves 69 VIVUS Announces 69 Initiates Clinical 69 Beta Blocker 69 Surgical Procedures 69 Q3 Loss Widens 69 R lenalidomide 69 Receives Orphan Drug 69 Nicotine Vaccine 69 Initiates Dosing 69 Metabolic Disorder 69 Left Ventricular 69 Artery Disease 69 Useful Tool 69 Earns Milestone Payment 69 High Growth Forecasted 69 Helps Improve 69 Skeletal Muscle 69 Achieves Primary Endpoint 69 Long Term Survival 69 Achieves Significant 69 Collaborators Present 69 Announces Presentation 69 Deliver Comprehensive 69 Liver Failure 69 Estrogen Therapy 69 Addresses Growing 69 Reduces Debt 69 Announces Discontinuation 69 Q2 Loss Narrows 69 Unveils Enhanced 69 Shows Statistically Significant 69 Completes Divestiture 69 Flagship Product 69 FDA APPROVES 69 Submits Biologics License Application 69 Q1 Loss Narrows 69 Mg Usa 69 Eur J 69 Jointly Offer 69 Launches Unique 69 Prolongs Life 69 Spectrum Pharmaceuticals Announces 69 Signs Licensing Agreement 69 Provides Update Regarding 69 Less Invasive 69 Improves Patient 69 Ischemic Stroke 69 FDA Clearance 69 Acquisition Strengthens 69 Licenses Novel 69 Revenues Decline 69 Complicated Skin 69 Pain Medications 69 Pre Cancerous 69 Announces Successful Completion 69 Novel Treatments 69 Blood Thinner 69 Solution Achieves 69 Issues Guidance 69 Relapsing Remitting Multiple Sclerosis 69 Successfully Complete 69 Net Loss Narrows 69 Treatment Experienced 69 Predict Risk 69 Study Casts Doubt 69 Antifungal 69 Adjuvant Chemotherapy 69 Investigational Treatment 69 Polymerase Inhibitor 69 Infected Patients 69 Tumor Cell 69 Present Webinar 69 Testosterone Gel 69 BioElectronics Announces 69 Strongly Linked 69 Refractory Hodgkin Lymphoma 69 Q1 Loss Widens 69 Improve Outcomes 69 Pain Relievers 69 Revises Guidance 69 Myeloma Patients 69 Treatment Regimen 69 Enables Organizations 69 Q3 Loss Narrows 69 Disease Progression 69 Lung Cancer Trial 69 Study Shows 69 See CLINICAL PHARMACOLOGY 69 Stabilizes 69 Gene Variants 69 Hsp# Inhibitor 69 Fortifies 69 Q2 Loss Widens 69 Extends Reach 69 Results Confirm 69 Unveils Breakthrough 69 Medoxomil 69 Develops Innovative 69 Experts Advise 69 Lung Cancer Drug 69 Unveils Groundbreaking 69 Demonstrate Significant 69 Significantly Expands 69 Steep Rise 69 Presents Positive Preclinical 69 Randomized Double Blind 69 Breast Cancer Patients 69 Chronic Sinusitis 69 Cholesterol Drug 69 Could Save Lives 69 Diabetic Neuropathy 69 Delivers Comprehensive 69 Embolic 69 Awarded Patents 69 Chemotherapy Induced 69 Obtains Approval 69 Increases Efficiency 69 #-# Full Text 69 Glucose Control 69 Antipsychotic Drugs 69 Blood Clot Risk 69 Confirms Commitment 69 Milestone Achieved 69 Asthma Treatment 69 Sees Continued 69 Q4 Loss Widens 69 Gene Linked 69 Premature Infants 69 Migraine Headaches 69 Efficacy Trial 69 Higher Doses 69 Voluntarily Withdraws 69 Offers Affordable 69 Anemia Drug 69 Protein Synthesis 69 Initiates Phase 2b 69 Revolutionizes 69 Total Knee Arthroplasty 69 Hypercholesterolemia 69 Provide Enhanced 69 Announces Definitive Agreement 69 Regains Compliance With 69 Technicals Showing Bullish 69 Vaginal Gel 68 More Than Doubled 68 Reduces Costs 68 Statin Drugs 68 Renews Agreement 68 Stent Implantation 68 Serious Side Effects 68 Receives Fast Track 68 Study Concludes 68 Receives CE Marking 68 Dialysis Patients 68 Treatment Naïve 68 Antitumor 68 More Than Doubles 68 Urine Test 68 Hydrochlorothiazide Tablets 68 Being Evaluated 68 Epilepsy Drugs 68 Achieve Significant 68 Device Helps 68 Develop Next Generation 68 Postmenopausal Osteoporosis 68 Treatment Naive Patients 68 Submits Supplemental 68 Successfully Treated 68 See WARNINGS 68 Study Links 68 Licenses Patents 68 Antidepressants Linked 68 Endometrial Cancer 68 Strengthens Leadership 68 Renal Cancer 68 Randomized Clinical Trials 68 Taro Receives 68 Capsules CII 68 Glucose Levels 68 Blood Clots 68 Contrast Agent 68 Predict Dementia 68 Unveils Expanded 68 Panic Disorder 68 Signs Agreements 68 Injectable Gel 68 Momentum Grows 68 HER2 Positive Breast Cancer 68 Vaccine Adjuvant 68 Lung Cancer Patients 68 Boosts Survival 68 Oral Calcitonin 68 Metastatic Renal Cell Carcinoma 68 Help Prevent 68 Accelerates 68 Substantially Reduce 68 Lower Blood Pressure 68 Enters Agreement 68 Penetrates 68 Increased Mortality 68 Accurately Predicts 68 Remains Flat 68 ZMGD.PK 68 Aggressive Prostate Cancer 68 Pregnancy Linked 68 Help Predict 68 Begins Shipping 68 Immune Responses 68 HCV Protease Inhibitor 68 Peginterferon Alfa 2a 68 Virus Infection 68 Inflammatory Arthritis 68 Tablet Formulation 68 Respiratory Distress 68 Radiation Doses 68 Carotid Artery Stenting 68 Commences Phase 68 Radical Prostatectomy 68 Stockholders Approve Acquisition 68 TriCo Bancshares Announces 68 Chemotherapy Regimen 68 Plus Ribavirin 68 Accelerates Growth 68 Menopausal Women 68 Extended Release 68 Prevent Stroke 68 Could Revolutionize 68 Stent Placement 68 Sees Positive 68 Minimally Invasive Treatment 68 Milestone Payment 68 Pose Serious 68 Initiates Phase 68 Fondaparinux 68 Sustained Reduction 68 Gains Traction 68 Investigational Oral 68 Efficacious 68 Vitamin D Linked 68 Recall Issued 68 Urinary Tract Infections 68 Phase 2a Clinical Trial 68 Stable Angina 68 Cholesterol Drugs 68 Report Examines 68 Subgroup Analysis 68 Sleep Disturbances 68 Chronic Renal Failure 68 Expand Relationship 68 Novel Inhibitor 68 Physical Function 68 Announces Availability 68 Achieves Prestigious 68 Builds Momentum 68 Liver Damage 68 Introduces Affordable 68 Blood Glucose 68 Inhaled Nitric Oxide 68 Electrical Stimulation 68 Regains NASDAQ 68 Cites Positive 68 Pending Acquisition 68 Solution Enables 68 Pulmonary Artery 68 Larger Than Expected 68 Product Offerings 68 Provides Preliminary 68 Localized Prostate Cancer 68 Prostate Tumors 68 Parathyroid Hormone 68 Metastatic Colorectal Cancer 68 Saves Money 68 Dramatic Increase 68 Post Operative 68 Significant Reductions 68 Delivers Powerful 68 Higher Than Expected 68 Molecular Mechanism 68 Radiofrequency Ablation 68 Enables Faster 68 Sirolimus Eluting 68 Preterm Labor 68 Suppresses 68 Inhaled Insulin 68 Alert Technicals Showing Bearish 68 Forecast Quick Facts 68 Preclinical Study 68 Investigational Agent 68 Announces Expanded 68 JAK2 Inhibitor 68 Hepatic Encephalopathy 68 Optimizes 68 Complete Merger 68 Migraine Pain 68 Demonstrates Ability 68 Launches Innovative 68 Prostate Cancer Vaccine 68 Hyperlipidemia 68 Customizes 68 IN PATIENTS WITH 68 Receives NASDAQ 68 Hormone Refractory Prostate Cancer 68 Allergic Reactions 68 Regenerative Cells 68 Relapsed Multiple Myeloma 68 Deliver Enhanced 68 Randomized Controlled Trial 68 Randomized Placebo Controlled Trial 68 Receives Notification 68 Above Consensus 68 Disease Modifying 68 REMINDER ORLive Presents 68 Multiple Myeloma Patients 68 Announces Favorable 68 Acquire Assets 68 Drop Sharply 68 Genes Predict 68 Neuroendocrine Tumors 68 Non Inferiority 68 Streamlines Operations 68 Reperfusion Injury 68 Placebo Controlled Trial 68 Rat Poison Found 68 Clinically Significant 68 Receives Approval 68 Pulmonary Arterial Hypertension 68 Proton Pump Inhibitors 68 First Patient Treated 68 Glycemic Control 68 Coverage Initiated 68 Delivers Improved 68 에 을 68 Antiplatelet 68 Technicals Showing Bearish 68 Announce Expanded 68 Neoadjuvant Chemotherapy 68 Long Term Outcomes 68 Phase Ib Clinical Trial 68 Pharmaceuticals Initiates 68 ST Elevation Myocardial 68 Reinforces Importance 68 II Clinical Trial 68 Heartburn Drugs 68 Invasive Fungal Infections 68 Expects Higher 68 Improves Accuracy 68 Inflammatory Markers 68 Solution Helps 68 Reduces Size 68 Momentum Continues 68 Fifth Consecutive Year 68 Tremendous Growth 67 Subsidiary Enters 67 Modulates 67 Strengthens Its 67 Broadens Its 67 Contrast Enhanced 67 Confirmatory Phase 67 Parenteral Nutrition 67 Colorectal Cancer Risk 67 Genes Involved 67 Releases Latest Version 67 Patents Covering 67 Hematological Cancers 67 Unveils Innovative 67 Survey Indicates 67 IrelandRESEARCH AND MARKETS 67 Posts Wider Loss 67 Schizophrenia Drug 67 Board Authorizes 67 Alpha interferons including 67 Gastric Cancer 67 Exceeds Expectations 67 Demystifies 67 R brand levalbuterol 67 Prognostic Significance 67 Newly Identified 67 Unveils Latest Version 67 Diabetic Foot Ulcers 67 Smallpox Vaccine 67 Could Predict 67 Testosterone Patch 67 Severe Acne 67 Completes Successful 67 Rises Sharply 67 Announce Receipt 67 Amends Agreement 67 Treatment Resistant 67 Drug Combo 67 Drops Sharply 67 Vertebral Fractures 67 PROCTOCORT R 67 Dips Slightly 67 Smoking Linked 67 Begins Clinical Trial 67 Atypical Antipsychotics 67 NICE Recommends 67 Peginterferon 67 Successfully Completes 67 Explore Strategic Alternatives 67 Revenue Grows 67 Monetizes 67 Cinacalcet 67 Expands Availability 67 Acute Ischemic Stroke 67 Antibiotic Treatment 67 Clinical Study Shows 67 Pivotal Trial 67 First Patient Dosed 67 Demonstrates Potent 67 Kidney Transplant Patients 67 Atopic Dermatitis 67 Iron Deficiency 67 Extends Tender Offer 67 Fully Featured 67 First Patient Enrolled 67 Files Investigational 67 Therapeutic Competitors Companies 67 Castration Resistant Prostate Cancer 67 Extends Collaboration 67 Up Sharply 67 ergot derivatives 67 Sees Steady 67 Bepreve TM 67 ORADUR ® 67 Provides Updates 67 Pivotal Phase III 67 Drug Eluting 67 Benign Prostatic Hyperplasia 67 Leading Provider 67 Provides Updated 67 Expands Offerings 67 Host Webinar 67 novel orally inhaled 67 Unveils Newest 67 Intrathecal 67 Revenues Increase 67 Lanthanum Carbonate 67 Successfully Integrates 67 Updates Guidance 67 Cypher Sirolimus 67 Chemotherapeutic Agents 67 Pivotal Phase 67 &Amp; 67 Phase III Trials 67 Hip Fractures 67 Non Invasive 67 Report Assesses 67 Demonstrates Interoperability 67 Chemotherapy Improves 67 TO AVOID PREGNANCY WHILE 67 Randomized Study 67 Hemoglobin Levels 67 Protein Linked 67 Renal Artery 67 Presents Preclinical 67 Cancer Cells 67 Treatment Naive 67 Signs Reseller Agreement 67 Wins Approval 67 Thrombotic 67 FOR WELL BEING 67 Officially Launches 67 Significantly Enhances 67 Renal Impairment 67 Serious Infections 67 Cognitive Decline 67 Terminates Contract 67 Seasonal Allergic Rhinitis 67 Adjunctive 67 Achieves SAS 67 Introduces Expanded 67 Achieves Cisco 67 Fall Sharply 67 Cardiac Function 67 Mutually Agree 67 Clinically Proven 67 R famotidine 67 Provides Detailed 67 Solution Integrates 67 Telaprevir VX 67 Rise Sharply 67 Catheter Associated 67 Expands Reach 67 Productivity Gains 67 Tumor Targeting 67 Announces Termination 67 Chronic Bronchitis 67 Offers Enhanced 67 Achieves Certification 67 Solidifies Position 67 Drug Resistant 67 Gum Disease 67 Positively Impacts 67 Hormone Therapy 67 Achieves ISO #:# Certification [002] 67 Topical Treatment 67 Drug Coated Stent 67 Oral Mucositis 67 Seamless Integration 67 Who Underwent 67 Receives Complete Response 67 Therapeutic Potential 67 Demand Grows 67 Therapy Shows Promise 67 Rapidly Growing 67 Pegylated Liposomal Doxorubicin 67 Enters Into Exclusive 67 Bone Fractures 67 Announce Launch 67 Dose Escalation 67 Validates 67 Osteoarthritis Patients 67 Replicates 67 Partial Onset Seizures 67 Results Reflect 67 Skin Lesions 67 Dose Ranging Study 67 Primary Hypercholesterolemia 67 Insulin Pen 67 Posts Strong 67 Stem Cell Treatment 67 Laryngeal Cancer 67 Receives Unsolicited 67 Improve Efficiency 67 Prospective Randomized 67 Antibiotic Use 67 Gene Mutation 67 Extends Capabilities 67 Cardiovascular Prosthetic Devices 67 Reports Preclinical Data 67 Extends Maturity 67 Dramatically Expands 67 Left Atrial 67 Obtains FDA 67 Sees Significant 67 Viral Suppression 67 AUDIO PROVIDED BY 67 Recombinant Human 67 Demonstrates Commitment 67 Announces Underwriters Exercise 67 Receives Notice 67 Tiotropium 67 Sinks Lower 67 Ticks Higher 67 Develop Innovative 67 Deliver Integrated 67 IND Filing 67 Postherpetic Neuralgia 67 Reveals Significant 67 ACE Inhibitors 67 Acquires Controlling Interest 67 Eradicates 67 Pulsatile 67 DIURIL R 67 Autologous Stem Cell Transplantation 67 Speeds Up 67 Flamel Technologies Announces 67 Prostate Surgery 67 Hosts Webinar 67 Announces Stockholder Approval 67 Metastatic Melanoma 67 Study Uncovers 67 Anemia Drugs 67 Platelet Inhibition 67 Therapeutic Efficacy 67 Drug Coated Stents 67 Shortens 67 Physician Insights 67 Deep Venous Thrombosis 67 Immune Cells 67 Previously Announced 67 JAK Inhibitor 67 Lung Cancer Survival 67 Generates Record 67 Redefines 67 Successfully Deploys 67 Files Shelf Registration Statement 67 Data Indicate 67 Rotavirus Vaccine 67 Help Improve 67 Recertified 67 Develops Novel 67 Dry Powder Inhaler